for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Tibet Rhodiola Pharmaceutical Holding Co

600211.SS

Latest Trade

48.12CNY

Change

-0.32(-0.66%)

Volume

3,359,526

Today's Range

47.41

 - 

48.29

52 Week Range

23.88

 - 

182.07

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
48.44
Open
48.29
Volume
3,359,526
3M AVG Volume
76.68
Today's High
48.29
Today's Low
47.41
52 Week High
182.07
52 Week Low
23.88
Shares Out (MIL)
247.94
Market Cap (MIL)
12,010.11
Forward P/E
26.04
Dividend (Yield %)
1.05

Next Event

Dividend For 600211.SS - 0.5100 CNY

Latest Developments

More

Tibet Rhodiola Pharmaceutical's Shareholder Plans To Unload Up To 2% Stake In The Company

Tibet Rhodiola Pharmaceutical's Board Elects Chairman

Tibet Rhodiola Pharmaceutical Plans Share Buyback Worth 70-140 Mln Yuan Within 12 Months

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Tibet Rhodiola Pharmaceutical Holding Co

TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The Company conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.

Industry

Major Drugs

Contact Info

No. 19, Beijing Middle Road

LASA, SIC

850000

China

+86.891.6835809

http://www.xzyy.cn

Executive Leadership

Dabin Chen

Chairman of the Board

Yucheng Zhou

Vice Chairman of the Board

Yuandong Guo

General Manager

Chunyan Yang

Deputy General Manager

Lan Liu

Secretary of the Board

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

1.0K

2019

1.3K

2020

1.4K

2021(E)

1.8K
EPS (CNY)

2018

0.857

2019

1.250

2020

1.690

2021(E)

1.860
Price To Earnings (TTM)
28.73
Price To Sales (TTM)
8.75
Price To Book (MRQ)
4.66
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.40
LT Debt To Equity (MRQ)
0.40
Return on Investment (TTM)
16.67
Return on Equity (TTM)
14.73

Latest News

Latest News

BRIEF-Tibet Rhodiola Pharmaceutical's Board Elects Chairman

* SAYS BOARD ELECTS CHEN DABIN AS CHAIRMAN Source text in Chinese: https://bit.ly/2WGuuKZ Further company coverage: (Reporting by Hong Kong newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up